TransCode Therapeutics Open Letter to Shareholders
TransCode Therapeutics Open Letter to Shareholders
Many shareholders rightly ask why this request. Some believe that the potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is no assurance that any good news will occur, will occur by the deadline required, or that the stock will rise after any such positive announcement(s). BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company:
波士顿，2024年11月12日（环球新闻社） - TransCode Therapeutics（纳斯达克股票代码：RNAZ）的董事会和管理层今天向公司股东发出了以下公开信：
Dear Shareholders,
亲爱的股东：
At our upcoming Special Meeting to be held November 22, shareholders are being asked to authorize our Board of Directors to effect a reverse split — only if the Board determines that doing so is necessary as described below.
在即将于11月22日举行的特别会议上，股东被要求授权我们的董事会进行股票的逆向分割 - 仅在董事会确定有必要这样做且如下所述。
Many shareholders rightly ask why this request. Some believe that the potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is no assurance that any good news will occur, will occur by the deadline required, or that the stock will rise after any such positive announcement(s).
很多股东合理地问为什么会有这个请求。一些人认为，可能会宣布额外的积极临床数据或其他利好消息将有利于我们的股价。然而，并不保证会有任何好消息发生，也不保证好消息将在所需的最后期限之前发生，或者股价会在任何这样的积极消息公布后上升。
A reverse split is NOT something directors or management wishes to do — we all hope it won't be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.
董事会或管理层不希望进行股票的反向分割—我们都希望不会需要这样做。但纳斯达克听证会批准延长我们的纳斯达克上市的前提是，股东授权进行股票的反向分割—如果有必要的话。如果我们的股票在2024年12月31日之前的任何十天期间收盘价达到每股1.00美元或更高，则不需要进行反向分割。
If our stock does not meet this Nasdaq requirement, and we do not have your vote in favor of the reverse split, Nasdaq will delist our stock. A Nasdaq delisting would in all likelihood have a material adverse effect on the value of our company and the value of your stock.
如果我们的股票不符合纳斯达克的要求，且没有您投票支持反向分割，纳斯达克将会从纳斯达克摘牌我们的股票。纳斯达克的摘牌很可能会对公司价值和您的股票价值产生重大不利影响。
Our assessment boils down to this: your vote is your decision about whether you support our efforts to maintain our Nasdaq listing. Given our need to raise additional capital as soon as possible to continue the clinical trial and other operations, we believe having our stock remain on Nasdaq is critical to raising the needed capital.
我们的评估归结为：您的投票决定了您是否支持我们维持纳斯达克上市的努力。鉴于我们迫切需要尽快筹集额外资金以继续临床试验和其他运营，我们相信公司股票继续在纳斯达克交易所上市对筹集所需资金至关重要。
TransCode's management and directors are unanimously determined to maintain our Nasdaq listing. This is why we need you to authorize the reverse split, with all of us hoping that we will not have to implement this decision.
TransCode的管理层和董事会一致决定维持我们的纳斯达克上市。这就是为什么我们需要您批准反向分割，希望我们不必实施这一决定。
We call for your understanding and greatly appreciate your support.
我们呼吁您的理解，并对您的支持表示衷心感谢。
Your Board and Management
董事会和管理层
For more information, please contact:
更多信息，请联系:
TransCode Therapeutics, Inc.
Tania Montgomery-Hammon, Business Development
tania.montgomery@transcodetherapeutics.com
TransCode Therapeutics, Inc.
蒂娜·蒙哥马利-哈蒙，业务发展
该发布为“转让性诉讼改革法”1995年版中“前瞻性声明”包含的信息，以下简称“本声明”，包括但不限于有关TransCode Therapeutics股票交易和其他转让市场可能发生的事项的陈述。 此类前瞻性声明均基于公司管理层目前关于未来的预期，受到一些风险和不确定性因素的影响，这些因素可能导致TransCode实际结果与预期结果不同。
